NEJM Paper Yields Positive Efficacy Results for Roche/Plexxikon's PGx Melanoma Drug
September 01, 2010
NEJM Paper Yields Positive Efficacy Results for Roche/Plexxikon's PGx Melanoma Drug
Although the study published in NEJM showed that 81 percent of melanoma patients responded to PLX4032, some questions remain about how and why patients are developing resistance to the therapy, and whether the drug improves overall survival.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Roche Says FDA-Approved BRAF Test Is Better Than Sanger-based LDTs, but is it Enough to Sway Labs?
September 28, 2011 / Pharmacogenomics Reporter - Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma
May 18, 2011 / Pharmacogenomics Reporter - FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter - Clovis on Track to Unveil Data on New Personalized Pancreatic Cancer Treatment Option by Year End
October 10, 2012 / Pharmacogenomics Reporter - Plexxikon Launching Phase I/II Trial for PLX3397 in AML Patients with Flt3 Mutations
December 14, 2011 / Pharmacogenomics Reporter